12 Oversold NASDAQ Stocks to Buy Now
On July 14, Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.
Newamsterdam Pharma Co N.v. (NAMS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 10,138,938 | $183,616,167 | 3.09% | |
| 2. | Viking Global Andreas Halvorsen | 6,978,534 | $126,381,251 | 0.37% | |
| 3. | Deerfield Management James E. Flynn | 5,115,953 | $92,649,909 | +25% | 1.68% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 3,013,009 | $54,565,593 | +55% | 0.09% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 2,517,779 | $45,596,978 | +12% | 0.24% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.70 | 660 | $15,638.90 | 3,028,524 | 2025-09-15 | Filing | |
| $24.99 | 1,260 | $31,487.40 | 3,027,864 | 2025-09-08 | Filing | |
| $23.98 | 471 | $11,293.97 | 3,026,604 | 2025-08-11 | Filing | |
| $18.26 | 1,260 | $23,011.63 | 3,026,133 | 2025-06-25 | Filing | |
| $18.43 | 2,520 | $46,454.44 | 3,024,873 | 2025-06-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.11 | 96,896 | $2,529,954.56 | 15,000 | 2025-09-09 | Filing | |
| $25.31 | 53,104 | $1,344,062.24 | 111,896 | 2025-09-09 | Filing | |
| $25.09 | 18,073 | $453,451.57 | 15,000 | 2025-09-03 | Filing | |
| $24.86 | 8,269 | $205,567.34 | 15,000 | 2025-08-25 | Filing | |
| $25.49 | 7,658 | $195,202.42 | 69,302 | 2025-08-22 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,869,565 | $81,610,429 | 10.96% | |
| 2. | 23,960 | $681,422 | 0.02% | |
| 3. | 19,300 | $548,892 | 0% | |
| 4. | 12,900 | $418,992 | 0.25% | |
| 5. | 9,100 | $258,804 | 0% |
News See All
NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel
According to the firm, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a distinct late-stage cardiovascular company with a short-term trajectory toward regulatory filings.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
Billionaire Andreas Halvorsen's 10 Stock Picks With Huge Upside Potential
Ole Andreas Halvorsen is one of the prominent names among former employees of Julian Robertson's Tiger Management.
11 Best Guru Stocks to Buy According to Wall Street Analysts
Wall Street seems to be breathing a little easier after the initial panic over President Trump’s tariffs earlier this month, but the rollercoaster is not over just yet.
10 Oversold Biotech Stocks to Buy Now
Biotechnology stocks are among the most volatile in the market, primarily due to the high risks associated with their performance.
14 Best 52-Week High Stocks To Buy According to Analysts
After two years of substantial gains to record highs, exhaustion in the US equity markets is slowly kicking in.
10 Top Performing European Stocks Heading into 2025
As per Deloitte, inflation in the Eurozone slightly rebounded in October but was still quite low. The consumer price index increased 2% in October as compared to the year earlier.
15 Top Performing European Stocks So Far in 2024
In this piece, we will take a look at the 15 top performing European stocks so far in 2024.
Hedge Fund Resource Center Billionaire Hedge Funds
